23andMe announces layoffs totaling 40% of workforce, discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe cuts 40% of its workforce and discontinues therapeutics division
23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe on Monday.
23andMe to Cut 40% of Its Staff Amid Grim Financials
If you buy through affiliate links, we may earn commissions, which help support our testing. DNA testing company 23andMe is laying off 200+ employees, or about 40% of its workforce. The job cuts are part of a business restructuring to reduce costs ...
23andMe to lay off 40% of its workforce as stock price plummets
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what this means for its customers.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe is laying off 40 percent of its staff
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs will impact 40 percent of the genetic testing company’s workforce. 23andMe CEO and co-founder Anne Wojcicki said in a statement released on Monday that the staff reduction would save the beleaguered company more than $35 million.
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival. The once-popular DNA-testing site will also halt work on therapies it was developing.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,
Hosted on MSN6h
With 23andMe Struck by Layoffs, Can You Delete Genetic Data? Here's What We Know
In the wake of a big data breach and a sizable new round of layoffs, concerns about the 23andMe's handling of sensitive ...
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...
23andMe is ending its cancer research program and slashing over 200 jobs
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
Yahoo4h
What happens to customer data as 23andMe goes out of business?
Millions of people have sent their DNA to be analyzed by 23andMe in order to learn their genealogy and risk for certain ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
NBC Los Angeles1d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
23andMe’s stock turns lower after company posts its latest quarterly loss
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, shedding ...
23andMe warns of ‘substantial doubt’ over its survival without new funding
Genetics-testing company 23andMe has warned there is “substantial doubt” over its continued survival unless it raises new ...